Physician profile
Vinod Mishra
NPI 1265580724
$8,993.43
in general payments reported to CMS, 2019-2025
27 companies · $873 in 2025
The $873 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,982 · 2020: $826 · 2021: $1,395 · 2022: $2,089 · 2023: $1,113 · 2024: $715 · 2025: $873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,702.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,701.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,657.77 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $629.29 | 2019-2024 | Xifaxan, Trulance |
| Allergan, INC. | $492.86 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $487.03 | 2021-2023 | Zeposia |
| Gilead Sciences, INC. | $378.26 | 2019-2025 | Livdelzi |
| Takeda Pharmaceuticals U.S.A., INC. | $374.87 | 2019-2024 | Entyvio |
| Janssen Biotech, INC. | $373.21 | 2019-2023 | Stelara |
| Janssen Scientific Affairs, LLC | $307.52 | 2019-2022 | |
| Pfizer INC. | $301.72 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $291.81 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $214.52 | 2022-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $181.92 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $158.09 | 2023-2025 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $145.01 | 2024 | Iqirvo |
| Celltrion USA INC. | $144.30 | 2024 | Zymfentra |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $138.04 | 2025 | Rezdiffra |
| Abbott Laboratories | $137.50 | 2019 | |
| Intuitive Surgical, INC. | $93.27 | 2022 | |
| Merck Sharp & Dohme LLC | $88.83 | 2019-2023 | Dificid |
| Braintree Laboratories, INC. | $79.69 | 2022 | |
| Ferring Pharmaceuticals INC. | $68.65 | 2020-2022 | |
| Celgene Corporation | $57.84 | 2021-2023 | Zeposia |
| Biosense Webster, INC. | $55.26 | 2022 | |
| Shionogi INC | $49.05 | 2019 | |
| Redhill Biopharma INC. | $48.27 | 2021-2022 | |
| Boston Scientific Corporation | $20.13 | 2021 | |
| Novo Nordisk INC | $18.72 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vinod Mishra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.